Sandostatin LAR
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
| 84 | Sarcoidosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 2 |
| 227 | Osler disease | 1 |
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 175 / Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
193. Prader-Willi syndrome
Clinical trials : 128 / Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
227. Osler disease
Clinical trials : 57 / Drugs : 60 - (DrugBank : 20) / Drug target genes : 25 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|